Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Clearmind Medicine Inc. announced the publication of a U.S. patent application for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), targeting binge behavior disorders. This therapy addresses multiple binge behaviors, including excessive alcohol consumption, binge eating, smoking, compulsive shopping, and problematic sexual conduct. The combination leverages MEAI’s neuroplastic properties to reduce impulsivity and reward-seeking behavior, which, together with PEA, has shown a synergistic pharmacological effect, potentially offering a breakthrough in treating substance use disorders and addictions. This publication builds on Clearmind’s intellectual property portfolio, which includes 13 patents related to its collaboration with SciSparc Ltd. The company aims to pioneer safe and effective, next-generation treatments for binge behaviors and address significant unmet needs in addiction medicine.